The RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027.
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes that are responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the RNAi Therapeutics market growth during the forecast period.However, high cost involved in the development of RNAi therapies is likely to restraint the growth of the market during the forecast years.
Lucrative Regions for RNAi Therapeutics Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Growing Investments in RNAi Therapies
Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of the outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in September 2018, Curamir Therapeutics, Inc. received initial financial aid of US$ 10 million from Delos Capital to develop miRNA-based drugs for chemotherapy-resistant cancer. Also, in April 2019, Alnylam Pharmaceuticals Inc. announced its strategic partnership with Regeneron Pharmaceuticals to discover and commercialize RNAi therapeutic platform for the treatment of diseases associated with eye, central nervous system, and liver. The companies have invested about US$ 1 billion in the collaboration. Furthermore, in January 2020, Dicerna Pharmaceuticals, Inc. and Novo Nordisk collaborated to develop RNAi therapies for the treatment of liver diseases and cardiometabolic disorders. Dicerna Pharmaceuticals, Inc. received an upfront payment of ~US$ 175 million from Novo Nordisk for the initiation of the project. Furthermore, according to the terms in partnership, Dicerna Pharmaceuticals, Inc. will receive nearly US$ 25 million annually from Novo Nordisk for the first three years for the development of the product. Such investments help biotech and pharma companies not only launch new products but also increase the number of approved products. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received an approval from the US Food and Drug Administration (FDA) for its Onpattro infusion therapy used for the treatment of peripheral nerve disease (polyneuropathy). The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.
Molecule Type-Based Insights
Based on molecule type, the RNAi therapeutics market is segmented into small interfering RNAs (siRNA) and microRNA (miRNA). The small interfering RNAs (siRNA) segment held a larger share of the market in 2019. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Further, the MicroRNA (miRNA) segment is expected to register higher CAGR in the global RNAi therapeutics market during the forecast period.
Global RNAi Therapeutics Market, by Molecule Type– 2019& 2027
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Application-Based Insights
Based on application, the RNAi therapeutics market is segmentedinto oncology, cardiovascular, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others. In 2019, the oncology segment accounted for the largest share ofthe global RNAi therapeutics market owing to increasing preference for RNAi therapies for the treatment of cancer. Moreover, growing number of research collaborations in the field of oncology are also projected to drive the segment growth by 2027. However, cardiovascular disorders segment is estimated to register the highest CAGR in the market during the forecast period.
Route of Administration-Based Insights
Based on route of administration, the RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intradermal injections, intraperitoneal injections, and others. In 2019, the pulmonary delivery segment accounted for the largest share of the global RNAi therapeutics market. However, intravenous injectionssegment is estimated to register the highest CAGR in the market during the forecast period. Significant number or product launches and higher adoption of intravenous injectionare likely to have a positive impact on the segment growth.
End User-BasedInsights
Based on end user, the RNAi therapeutics market is further segmented into research and academic laboratories, hospitals, and diagnostic laboratories. The research and academic laboratoriessegment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
RNAi Therapeutics Market: Strategic Insights
Market Size Value in US$ 618.79 Million in 2019 Market Size Value by US$ 1,209.29 Million by 2027 Growth rate CAGR of 8.8% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
RNAi Therapeutics Market: Strategic Insights
| Market Size Value in | US$ 618.79 Million in 2019 |
| Market Size Value by | US$ 1,209.29 Million by 2027 |
| Growth rate | CAGR of 8.8% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Product launches and expansion strategiesarecommonly adopted by the companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the RNAi therapeutics marketadopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.
The global impacts of COVID-19 are being felt across several markets. In case of pharmaceutical industry, supply chain operations are significantly hampered due to the pandemic. However, market players in the RNAi therapeutics are focusing on the development of vaccine with the help of gene silencing technology, which might have a positive impact on the market growth during the forecast period.
By Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
RNAi TherapeuticsMarket– By Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
Asia Pacific(APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
South and Central America (SAM)
- Brazil
- Argentina
- Rest of SAM
Company Profiles
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Olix Pharmaceuticals, Inc.
- Glaxosmithkline Plc.
- Benitec Biopharma
- Arbutus Biopharma Corporation
- Silence Therapeutics
- Rexahn Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
- Quark
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Molecule Type ; Application ; Route of Administration ; End User , and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes.
The factors that are driving growth of the market are growing investments in RNAitherapies and rising prevalence of chronic conditions and infectious diseases.Moreover, strategic activities by the manufacturersare offering lucrative opportunities for the growth of the market.
The RNAi therapeutics market majorly consists of the players such as Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and Quark amongst others.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global RNAi Therapeutics Market – By Molecule Type
1.3.2 Global RNAi Therapeutics Market – By Application
1.3.3 Global RNAi Therapeutics Market – By Route of Administration
1.3.4 Global RNAi Therapeutics Market – By End User
1.3.5 Global RNAi Therapeutics market – By Geography
2. RNAi Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global RNAi Therapeutics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa (MEA) – PEST Analysis
4.2.5 South and Central America (SCAM) – PEST Analysis
4.3 Expert Opinions
5. RNAi Therapeutics Market– Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Growing Investments in RNAi Therapies
5.1.2 Rising Prevalence of Chronic Conditions and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost for RNAi Therapy Development
5.3 Market Opportunities
5.3.1 Significant Number of Pipeline Candidates for Strategic Alliances
5.4 Future Trends
5.4.1 Rising Emphasis on RNA Technologies
5.5 Impact analysis
6. RNAi Therapeutics Market – Global Analysis
6.1 Global RNAi Therapeutics Market Revenue Forecast and Analysis
6.2 Global RNAi Therapeutics Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. RNAi Therapeutics Market– Molecule Type
7.1 Overview
7.2 RNAi Therapeutics Market Share, Molecule Type, 2019 and 2027 (%)
7.3 Small Interfering RNAs (siRNA)
7.3.1 Overview
7.3.1.1 Small Interfering RNAs (siRNA): RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
7.4 MicroRNA (miRNA)
7.4.1 Overview
7.4.1.1 MicroRNA (miRNA) Market: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8. RNAi Therapeutics Market– Application
8.1 Overview
8.2 RNAi Therapeutics Market Share, Application, 2019 and 2027 (%)
8.3 Genetic Disorders
8.3.1 Overview
8.3.1.1 Genetic Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.4 Oncology
8.4.1 Overview
8.4.1.1 Oncology: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.5 Neurodegenerative Disorders
8.5.1 Overview
8.5.1.1 Neurodegenerative Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.6 Cardiovascular Disorders
8.6.1 Overview
8.6.1.1 Cardiovascular Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.1.1 Respiratory Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.8 Infectious Diseases
8.8.1 Overview
8.8.1.1 Infectious Disease: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.9 Renal Diseases
8.9.1 Overview
8.9.1.1 Renal Diseases: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
8.10 Other Disorders
8.10.1 Overview
8.10.1.1 Other Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
9. RNAi Therapeutics Market Market– Route of Administration
9.1 Overview
9.2 RNAi Therapeutics Market Share, Route of Administration, 2019 and 2027 (%)
9.3 Intradermal Injections
9.3.1 Overview
9.3.1.1 Intradermal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
9.4 Pulmonary Delivery
9.4.1 Overview
9.4.1.1 Pulmonary Delivery: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
9.5 Intravenous Injections
9.5.1 Overview
9.5.1.1 Intravenous Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
9.6 Intraperitoneal Injections
9.6.1 Overview
9.6.1.1 Intraperitoneal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
9.7 Other Route of Administrations
9.7.1 Overview
9.7.1.1 Others: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
10. RNAi Therapeutics Market Market– End User
10.1 Overview
10.2 RNAi Therapeutics Market Share, End User, 2019 and 2027 (%)
10.3 Diagnostic Laboratories
10.3.1 Overview
10.3.1.1 Diagnostic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
10.4 Research and Academic Laboratories
10.4.1 Overview
10.4.1.1 Research and Academic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
10.5 Hospitals
10.5.1 Overview
10.5.1.1 Hospitals: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
11. RNAi Therapeutics Market – Geographic Analysis
11.1 North America: RNAi Therapeutics Market
11.1.1 Overview
11.1.2 North America: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.3 North America: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.1.4 North America: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.1.5 North America: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.1.6 North America: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.1.7 North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
11.1.8 US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 US: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.1.8.3 US: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.1.8.4 US: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.1.8.5 US: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.1.9 Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Canada: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.1.9.3 Canada RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.1.9.4 Canada: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.1.9.5 Canada: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.1.10 Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Mexico: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.1.10.3 Mexico: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.1.10.4 Mexico: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.1.10.5 Mexico: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.2 Europe: RNAi Therapeutics Market
11.2.1 Overview
11.2.2 Europe: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.2.3 Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.2.4 Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.2.5 Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.2.6 Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.2.7 Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
11.2.8 Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.8.1 Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.8.2 Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.2.8.3 Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.2.8.4 Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.2.8.5 Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.2.9 UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.9.1 UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.9.2 UK RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.2.9.3 UK RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.2.9.4 UK RNAi Therapeutics Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
11.2.9.5 UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)
11.2.10 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.10.1 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.10.2 France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.2.10.3 France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.2.10.4 France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.2.10.5 France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.2.11 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.11.1 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.11.2 Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.2.11.3 Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.2.11.4 Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.2.11.5 Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.2.12 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.12.1 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.2.12.2 Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.2.12.3 Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.2.12.4 Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.2.12.5 Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.3 Asia Pacific: RNAi Therapeutics Market
11.3.1 Overview
11.3.2 Asia Pacific: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.3.3 Asia Pacific: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.3.4 Asia Pacific: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.3.5 Asia Pacific: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.3.6 Asia Pacific: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.3.7 Asia Pacific: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
11.3.8 China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.8.1 China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.8.2 China: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.3.8.3 China: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.3.8.4 China RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.3.8.5 China RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.3.9 Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.9.1 Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.9.2 Japan: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.3.9.3 Japan: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.3.9.4 Japan RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.3.9.5 Japan RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.3.10 India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.10.1 India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.10.2 India: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.3.10.3 India: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.3.10.4 India RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.3.10.5 India RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.3.11 South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.11.1 South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.11.2 South Korea: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.3.11.3 South Korea: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.3.11.4 South Korea RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.3.11.5 South Korea RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.3.12 Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.12.1 Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.3.12.2 Australia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.3.12.3 Australia: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.3.12.4 Australia RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.3.12.5 Australia RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.4 Middle East & Africa: RNAi Therapeutics Market
11.4.1 Overview
11.4.2 Middle East & Africa: RNAi Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
11.4.3 Middle East & Africa: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.4.4 Middle East & Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.5 Middle East & Africa: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.4.6 Middle East & Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.4.7 Middle East & Africa: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
11.4.8 Saudi Arabia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.4.8.1 Saudi Arabia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.4.8.2 Saudi Arabia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.4.8.3 Saudi Arabia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.8.4 Saudi Arabia: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.4.8.5 Saudi Arabia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.4.9 UAE: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.4.9.1 UAE: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.4.9.2 UAE: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.4.9.3 UAE RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.9.4 UAE: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.4.9.5 UAE RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.4.10 South Africa: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.4.10.1 South Africa: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.4.10.2 South Africa: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.4.10.3 South Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.10.4 South Africa RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.4.10.5 South Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.5 South and Central America: RNAi Therapeutics Market
11.5.1 Overview
11.5.2 South and Central America: RNAi Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
11.5.3 South and Central America: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.5.4 South and Central America: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.5.5 South and Central America: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.5.6 South and Central America: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.5.7 South and Central America: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
11.5.8 Brazil: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.5.8.1 Brazil: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.5.8.2 Brazil: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.5.8.3 Brazil: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.5.8.4 Brazil: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.5.8.5 Brazil: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
11.5.9 Argentina: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.5.9.1 Argentina: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.5.9.2 Argentina: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)
11.5.9.3 Argentina: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)
11.5.9.4 Argentina: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)
11.5.9.5 Argentina: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)
12. Impact of COVID-19 Pandemic on Global RNAi Therapeutics Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Rest of World: Impact Assessment of COVID-19 Pandemic
13. RNAi Therapeutics Market –Industry Landscape
13.1 Overview
13.2 Growth Strategies in the RNAi Therapeutics Market, 2015-2020
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Alnylam Pharmaceuticals, Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Benitec Biopharma
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Sanofi
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 GlaxoSmithKline plc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Olix Pharmaceuticals, Inc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Arrowhead Pharmaceuticals, Inc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Quark
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Rexahn Pharmaceuticals, Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Silence Therapeutics
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Arbutus Biopharma
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. North America RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)
Table 2. North America RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 3. North America RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 4. North America RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 5. US RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 6. US RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 7. US RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 8. US RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 9. Canada RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 10. Canada RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 11. Canada RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. Canada RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 13. Mexico RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 14. Mexico RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. Mexico RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 16. Mexico RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 17. Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 18. Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 19. Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 20. Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 21. Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 22. Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 23. Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 24. Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 25. United Kingdom RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 26. United Kingdom RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 27. UK: RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million).
Table 28. UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)
Table 29. France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 30. France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 31. France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 32. France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 33. Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 34. Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 35. Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 36. Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 37. Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 38. Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 39. Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 40. Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 41. Asia Pacific RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)
Table 42. Asia Pacific RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 43. Asia Pacific RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 44. Asia Pacific RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 45. China RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 46. China RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 47. China RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 48. China RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 49. Japan RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 50. Japan RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 51. Japan RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 52. Japan RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 53. India RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 54. India RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 55. India RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 56. India RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 57. South Korea RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 58. South Korea RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 59. South Korea RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 60. South Korea RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 61. Incidence, Mortality and Prevalence by cancer site, Australia, 2018
Table 62. Australia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 63. Australia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 64. Australia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 65. Australia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 66. Middle East & Africa RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 67. Middle East & Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 68. Middle East & Africa RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 69. Middle East & Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 70. Saudi Arabia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 71. Saudi Arabia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 72. Saudi Arabia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 73. Saudi Arabia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 74. UAE RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 75. UAE RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 76. UAE RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 77. UAE RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 78. South Africa RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 79. South Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 80. South Africa RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 81. South Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 82. South and Central America RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)
Table 83. South and Central America RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 84. South and Central America RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 85. South and Central America RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 86. Brazil RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 87. Brazil RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 88. Brazil RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 89. Brazil RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 90. Argentina RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 91. Argentina RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 92. Argentina RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 93. Argentina RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 94. Recent Inorganic Growth Strategies in the RNAi therapeutics market
Table 95. Recent Organic Growth Strategies in the RNAi therapeutics market
Table 96. Glossary of Terms, RNAi Therapeutics Market
LIST OF FIGURES
Figure 1. RNAi Therapeutics Market Segmentation
Figure 2. RNAi Therapeutics Market Segmentation, By Region
Figure 3. RNAi Therapeutics Market Overview
Figure 4. Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market
Figure 5. APAC to Show Significant Growth During Forecast Period
Figure 6. RNAi Therapeutics Market, by Geography (US$ Million)
Figure 7. Global RNAi Therapeutics Market – Leading Country Markets (US$ Million)
Figure 8. Global RNAi Therapeutics Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East and Africa (MEA) PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. RNAi Therapeutics Market Impact Analysis of Driver and Restraints
Figure 15. Global RNAi Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027
Figure 16. Global RNAi Therapeutics Market – By Geography Forecast and Analysis – 2019- 2027
Figure 17. Market Positioning of Key Players in Global RNAi Therapeutics Market
Figure 18. RNAi Therapeutics Market Share, Molecule Type, 2019 and 2027 (%)
Figure 19. Small Interfering RNAs (siRNA): RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 20. MicroRNA (miRNA) Market: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 21. RNAi Therapeutics Market Share, Application, 2019 and 2027 (%)
Figure 22. Genetic Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 23. Oncology: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 24. Neurodegenerative Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 25. Cardiovascular Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 26. Respiratory Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 27. Infectious Disease: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 28. Renal Diseases: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 29. Other Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 30. RNAi Therapeutics Market Share, Route of Administration, 2019 and 2027 (%)
Figure 31. Intradermal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 32. Pulmonary Delivery: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 33. Intravenous Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 34. Intraperitoneal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 35. Others: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 36. RNAi Therapeutics Market Share, End User, 2019 and 2027 (%)
Figure 37. Diagnostic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 38. Research and Academic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 39. Hospitals: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)
Figure 40. North America: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 41. North America RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 42. North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 43. US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 44. Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 45. Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 46. Europe: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 47. Europe RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 48. Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 49. Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 50. UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 51. France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 52. Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 53. Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 54. Asia Pacific: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 55. Asia Pacific RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 56. China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 57. Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 58. India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 59. South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 60. Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 61. Middle East & Africa: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 62. Middle East & Africa RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 63. Middle East & Africa: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
Figure 64. Saudi Arabia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 65. UAE: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 66. South Africa: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 67. South and Central America: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 68. South and Central America RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 69. South and Central America: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
Figure 70. Brazil: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 71. Argentina: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 72. Impact of COVID-19 Pandemic in North American Country Markets
Figure 73. Impact of COVID-19 Pandemic in Europe Country Markets
Figure 74. Impact of COVID-19 Pandemic in Asia-Pacific Country Markets
Figure 75. Impact of COVID-19 Pandemic in Rest of World Country Markets
Figure 76. Growth Strategies in the RNAi Therapeutics Market, 2015-2020
The List of Companies - RNAi Therapeutics Market
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Olix Pharmaceuticals, Inc.
- Glaxosmithkline Plc.
- Benitec Biopharma
- Arbutus Biopharma Corporation
- Silence Therapeutics
- Rexahn Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
- Quark
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to RNAi Therapeutics Market
Aug 2020
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Aug 2020
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2020
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Aug 2020
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Aug 2020
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Aug 2020
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Aug 2020
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
Aug 2020